As patient demand for cannabis flower medicine in Australia and internationally accelerates, medicinal cannabis business Little Green Pharma (ASX: LGP) has launched its first ever dried flower cannabis medicine.
Currently, there is an under supply of medicinal cannabis flower product in Australia due to increasing demand from fierce price competition from an expanding pool of medicinal cannabis clinics and authorised prescribers.
LGP is doing its part to alleviate this shortfall with the launch of its LGP Flower THC 22 – Desert Flame product, a Schedule 8 medicine with a high tetrahydrocannabinol (“THC”) to CBD ratio product (THC 22%, CBD <1.0%).
Flower medicines are becoming increasingly popular with Australian doctors in prescribing to patients for quick onset of effects, mainly for breakthrough pain or to assist with sleep,” LGP Managing Director Fleta Solomon said.
“Importantly with this product, we are providing a new supply of high-quality, Australian grown medicinal cannabis flower in an under-supplied market, to assist prescribed patients with access to their medicine.”
LGP Flower range is grown and manufactured in the South West of WA and supplied as dried medicinal cannabis whole flowers. The product is available in a 15g container and is anticipated to be prescribed via inhalation using a vaporiser.
Flower medicine may be preferred over oil medicines for those patients requiring rapid treatment onset.
Today’s news comes after LGP received a firm purchase order from German pharmaceutical wholesaler DEMECAN for a significant new shipment of locally produced cannabis flower whileentering a binding Terms Sheet to acquire freehold properties on which its cultivation and manufacturing facilities are situated, as well as two adjacent freehold properties.
